12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Abilify aripiprazole regulatory update

The U.K.'s NICE issued a preliminary appraisal for Abilify ariprazole from Bristol-Myers and Otsuka to treat schizophrenia in patients ages 15-17 years. In the appraisal, NICE asked the companies to provide more data on the clinical and cost effectiveness of Abilify in the age group compared with each of the antipsychotics routinely used...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >